Breast Neoplasm

A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated wi… (full text at CIViC)

PMID 22418700 · Lin et al., 2012 · Open in CIViC

With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB recepto… (full text at CIViC)

PMID 22418700 · Lin et al., 2012 · Open in CIViC

This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment. 121 patients with HER2 overexpressing breast cancer with CNS recu… (full text at CIViC)

PMID 26596672 · Cortés et al., 2015 · Open in CIViC

In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or t… (full text at CIViC)

PMID 25537159 · Rimawi et al., 2015 · Open in CIViC

Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers. The irreversible TKI afati… (full text at CIViC)

PMID 25370464 · Ring et al., 2015 · Open in CIViC

Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (A… (full text at CIViC)

PMID 18725974 · She et al., 2008 · Open in CIViC

In a phase III, randomized, open-label trial, 408 women with HER2-positive, locally advanced or metastatic breast cancer that, after treatment with regimens that included an anthracycline, a taxane, a… (full text at CIViC)

PMID 17192538 · Geyer et al., 2006 · Open in CIViC

This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment. Patients were given capecitabine (n=161)… (full text at CIViC)

PMID 17192538 · Geyer et al., 2006 · Open in CIViC

In a phase III, randomized, double-blind, controlled trial, 219 post-menopausal women with HER2-positive, histologically confirmed stage IIIB/IIIC or IV estrogen receptor-positive and/or progesterone … (full text at CIViC)

PMID 19786658 · Johnston et al., 2009 · Open in CIViC

In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 po… (full text at CIViC)

PMID 22493419 · Guarneri et al., 2012 · Open in CIViC

This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells. In th… (full text at CIViC)

PMID 20124187 · Blackwell et al., 2010 · Open in CIViC

In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than s… (full text at CIViC)

PMID 22257673 · Baselga et al., 2012 · Open in CIViC

In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment. A marked synergistic… (full text at CIViC)

PMID 16091755 · Xia et al., 2005 · Open in CIViC

In this phase III, randomized, open-label trial, 536 patients with HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, with at least one being for metastatic disease. T… (full text at CIViC)

PMID 33480963 · Rugo et al., 2021 · Open in CIViC

In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 p… (full text at CIViC)

PMID 21358673 · Weigelt et al., 2011 · Open in CIViC

Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab (n=63) and trastuzumab-naive (n=64) cohorts in a Phase II trial. As for the primary endpoint, the 16-week… (full text at CIViC)

PMID 20142587 · Burstein et al., 2010 · Open in CIViC

A panel of HER2 positive breast cancer cell lines (n=12) displayed greater sensitivity to Neratinib (HKI-272) compared to triple negative breast cancer cell lines (n=15, p=.0002) and luminal breast ca… (full text at CIViC)

PMID 24009064 · Canonici et al., 2013 · Open in CIViC

Two HER2 positive breast cancer cells lines were 480-times more sensitive to Neratinib (HKI-272) compared to a HER2 negative breast cancer cell line (MDA-MB-435) as indicated by decreased proliferatio… (full text at CIViC)

PMID 15173008 · Rabindran et al., 2004 · Open in CIViC

A phase III clinical trial (NALA, NCT01808573) with a randomized parallel design of 621 patients evaluated the combination therapy of Neratinib plus capecitabine (N+C) (307 pts.) vs. Lapatinib plus ca… (full text at CIViC)

Open in CIViC

A Phase II clinical trial (NCT00741260 ) assessed the safety and efficacy of Neratinib plus capecitabine in the treatment of HER2 positive breast cancer patients. Of the 72 patients in this study, 65 … (full text at CIViC)

PMID 25287822 · Saura et al., 2014 · Open in CIViC

In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assesse… (full text at CIViC)

PMID 26874901 · Chan et al., 2016 · Open in CIViC

CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer. Patients were HER2-positive by IHC3+ or FIS… (full text at CIViC)

PMID 25693012 · Swain et al., 2015 · Open in CIViC

In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (1… (full text at CIViC)

PMID 22149875 · Baselga et al., 2012 · Open in CIViC

As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diass… (full text at CIViC)

PMID 22802530 · Utermark et al., 2012 · Open in CIViC

This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more … (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductio… (full text at CIViC)

PMID 22802530 · Utermark et al., 2012 · Open in CIViC

HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting. Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having… (full text at CIViC)

PMID 16236737 · Piccart-Gebhart et al., 2005 · Open in CIViC

A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration … (full text at CIViC)

PMID 11248153 · Slamon et al., 2001 · Open in CIViC

A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progres… (full text at CIViC)

PMID 15911866 · Marty et al., 2005 · Open in CIViC

In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab. Patients had 12 weeks or … (full text at CIViC)

PMID 19289619 · von Minckwitz et al., 2009 · Open in CIViC

In a phase 1 trial, patients with HER2-positive breast cancer were treated with Trastuzumab Deruxtecan (DS-8201a). The response rate was 59.5% (66/111).

PMID 31047803 · Tamura et al., 2019 · Open in CIViC

The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated. Patients were required to have prior exposure to trastuzumab and la… (full text at CIViC)

PMID 24793816 · Krop et al., 2014 · Open in CIViC

The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 p… (full text at CIViC)

PMID 23020162 · Verma et al., 2012 · Open in CIViC

In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrot… (full text at CIViC)

PMID 21172893 · Burris et al., 2011 · Open in CIViC

In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adver… (full text at CIViC)

PMID 23382472 · Hurvitz et al., 2013 · Open in CIViC

This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting. 8381 women we… (full text at CIViC)

PMID 26255196 · Zardavas et al., 2015 · Open in CIViC

Primarily based on the results from the phase III ExteNET clinical trial (Study 3004, NCT00878709), on July 17, 2017, the FDA approved neratinib (NERLYNX, HKI-272) for extended adjuvant therapy of adu… (full text at CIViC)

PMID 29523624 · Singh et al., 2018 · Open in CIViC

The initial 2 year follow-up of the Phase III clinical trial (exteNET, NCT00878709) where early stage HER2 positive breast cancer patients underwent adjuvant trastuzumab therapy and then either receiv… (full text at CIViC)

PMID 29146401 · Martin et al., 2017 · Open in CIViC